Harmony Biosciences Files 8-K

Ticker: HRMY · Form: 8-K · Filed: 2024-11-01T00:00:00.000Z

Sentiment: neutral

Topics: 8-k, disclosure

Related Tickers: HRMY

TL;DR

Harmony Biosciences filed an 8-K on Oct 30th, details TBD.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on November 1, 2024, reporting an event that occurred on October 30, 2024. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits' but does not provide specific details on the nature of these events or any associated financial figures within the provided text.

Why It Matters

This filing indicates a material event has occurred for Harmony Biosciences, requiring disclosure to investors. The lack of specific details in the provided text necessitates further investigation into the full filing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K disclosure and does not, in itself, indicate any immediate financial distress or significant negative event.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing for Harmony Biosciences?

The provided text does not specify the exact event, only that it falls under 'Other Events' and 'Financial Statements and Exhibits' and occurred on October 30, 2024.

When was this 8-K filing submitted to the SEC?

The filing was submitted on November 1, 2024.

What is Harmony Biosciences' principal executive office address?

The principal executive offices are located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

In which state is Harmony Biosciences incorporated?

Harmony Biosciences Holdings, Inc. is incorporated in Delaware.

What is the Commission File Number for Harmony Biosciences?

The Commission File Number for Harmony Biosciences is 001-39450.

From the Filing

0001104659-24-113484.txt : 20241101 0001104659-24-113484.hdr.sgml : 20241101 20241101160637 ACCESSION NUMBER: 0001104659-24-113484 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241101 DATE AS OF CHANGE: 20241101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241419112 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 tm2427273d1_8k.htm FORM 8-K false 0001802665 0001802665 2024-10-30 2024-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K         CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 30, 2024       HARMONY BIOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter)       Delaware 001-39450 82-2279923 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)     630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code)   ( 484 ) 539-9800 (Registrant’s telephone number, including area code)   N/A (Former name or former address, if changed since last report.)        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   HRMY   The Nasdaq Global Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨               Item 8.01 Other Events   On November 1, 2024, certain shareholders (the “Selling Shareholders”) of Harmony Biosciences Holdings, Inc. (the “Company”) sold 8,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”), in a registered public offering pursuant to the Company’s Registration Statement on Form S-3 ASR (File No. 333-260905)&#1

View on Read The Filing